UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database

Thoracic cancer, 2020-11, Vol.11 (11), p.3357-3364

2020

Volltextzugriff (PDF)

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC

JTO clinical and research reports, 2023-02, Vol.4 (2), p.100461-100461, Article 100461

2023

Volltextzugriff (PDF)

Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes

BioMed research international, 2010-01, Vol.2010, p.1-17

2010

Volltextzugriff (PDF)

Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib

The oncologist (Dayton, Ohio), 2019-05, Vol.24 (5), p.680-687

2019

Volltextzugriff (PDF)

Análisis de las intervenciones nutricionales en el proceso asistencial del paciente oncológico en Andalucía: el proyecto NOA

Nutrición hospitalaria : organo oficial de la Sociedad Española de Nutrición Parenteral y Enteral, 2021-08, Vol.38 (4), p.758-764

2021

Volltextzugriff (PDF)

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

BMC cancer, 2018-01, Vol.18 (1), p.106-106, Article 106

2018

Volltextzugriff (PDF)

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

The lancet oncology, 2018-04, Vol.19 (4), p.521-536

2018

Volltextzugriff (PDF)

PPD01.06 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-2 Study

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.e6-e7

2024

Volltextzugriff (PDF)

Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC

The New England journal of medicine, 2024-08, Vol.391 (7), p.585-597

2024

Volltextzugriff (PDF)

Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification ( MET amp) detected by liquid biopsy (LBx)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9121-9121

2022

Volltextzugriff (PDF)

An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS8600-TPS8600

2022

Volltextzugriff (PDF)

Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study

Journal of thoracic oncology, 2024-02, Vol.19 (2), p.285-296

2024

Volltextzugriff (PDF)

Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification ( MET amp)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9021-9021

2021

Volltextzugriff (PDF)

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Journal of clinical oncology, 2024-09

2024

Volltextzugriff (PDF)

Irinotecan-Induced Dysarthria

JNCI : Journal of the National Cancer Institute, 2001-09, Vol.93 (18), p.1419-1420

2001

Volltextzugriff (PDF)

Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9017-9017

2018

Volltextzugriff (PDF)

Abstract CT051: Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen mRNA vaccine BNT116 + docetaxel in patients with advanced non-small cell lung cancer

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT051-CT051

2024

Volltextzugriff (PDF)

Analysis of nutritional interventions in the care process of oncological patients in Andalusia - the NOA project

Nutrición hospitalaria : organo oficial de la Sociedad Española de Nutrición Parenteral y Enteral, 2021-07, Vol.38 (4), p.758-764

2021

Volltextzugriff (PDF)

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B

Cell reports. Medicine, 2023-11, Vol.4 (11), p.101280-101280, Article 101280

2023

Volltextzugriff (PDF)

Immune Microenvironment in Colorectal Cancer : A New Hallmark to Change Old Paradigms

Clinical & developmental immunology, 2011-01, Vol.2011 (2011), p.1-9

2011

Volltextzugriff (PDF)

Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes

BioMed research international, 2010, Vol.2010 (2010), p.1-17

2010

Volltextzugriff (PDF)

Immune Microenvironment in Colorectal Cancer: A New Hallmark to Change Old Paradigms

Journal of immunology research, 2010, Vol.2011 (2011), p.1-9

2010

Volltextzugriff (PDF)

Tumor de colisión. Adenocarcinoma y linfoma MALT gástrico sincrónicos

Medicina clínica, 2005-03, Vol.124 (8), p.318-319

2005

Volltextzugriff (PDF)

Collision tumour. adenocarcinoma and synchronous MALT gastric lymphoma

Medicina clínica, 2005-03, Vol.124 (8), p.318-319

2005

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(32)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Humans
(11)
Oncology
(9)
Female
(7)
Male
(6)
Aged
(5)
Lung Neoplasms - Drug Therapy
(5)
Adult
(4)
Antineoplastic Agents - Therapeutic Use
(4)
Cancer
(4)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(4)
Carcinoma, Non-Small-Cell Lung - Genetics
(4)
Lung Neoplasms - Genetics
(4)
Middle Aged
(4)
Chemotherapy
(3)
Erbb Receptors - Genetics
(3)
General & Internal Medicine
(3)
Lung Cancer
(3)
Medicine, General & Internal
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC

Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes

Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib

Análisis de las intervenciones nutricionales en el proceso asistencial del paciente oncológico en Andalucía: el proyecto NOA

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

PPD01.06 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-2 Study

Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC

Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification ( MET amp) detected by liquid biopsy (LBx)

An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer

Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study

Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification ( MET amp)

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Irinotecan-Induced Dysarthria

Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1

Abstract CT051: Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen mRNA vaccine BNT116 + docetaxel in patients with advanced non-small cell lung cancer

Analysis of nutritional interventions in the care process of oncological patients in Andalusia - the NOA project

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B

ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

Immune Microenvironment in Colorectal Cancer : A New Hallmark to Change Old Paradigms

Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes

Immune Microenvironment in Colorectal Cancer: A New Hallmark to Change Old Paradigms

Tumor de colisión. Adenocarcinoma y linfoma MALT gástrico sincrónicos

Collision tumour. adenocarcinoma and synchronous MALT gastric lymphoma

Suchergebnisse filtern